News
2d
TipRanks on MSNAbbVie’s Promising Phase 3 Study on Upadacitinib for Alopecia AreataAbbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study ...
3d
Zacks.com on MSNShould You Continue to Hold Thermo Fisher Stock in Your Portfolio Now?TMO's growth via acquisitions and product launches is strong, but macro pressures and FX headwinds cloud the outlook.
Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has ...
India's Sun Pharmaceutical has signed an agreement to acquire US biotech Concert Pharmaceuticals and its lead drug deuroxilitinib, in phase 3 testing for alopecia areata, a leading cause of hair loss.
Thermo Fisher continues its growth through acquisitions, innovative product launches, and a solid financial foundation. The ...
Alumni Nicole Friedland (Merrill ’89, community studies) and Brett King (Crown ’92, chemistry) both spoke at the National ...
Children of various racial and ethnic minority groups have a higher prevalence of alopecia areata than non-Hispanic White children.
Certain habits can make alopecia areata worse. Knowing what to avoid when you have alopecia areata may help prevent hair loss.
After they lost their hair, they found their voices. Now, two local teens and their families want to raise awareness about a lesser-known treatment for the condition that once robbed them of their ...
Alopecia areata is a prevalent autoimmune condition marked by non-scarring hair loss, affecting nearly 2% of the population during their lifetime. The condition involves the breakdown of the ...
Dear Reader: Alopecia areata is a chronic autoimmune disorder that results in hair loss, typically in rounded patches about the size of a quarter. The name is a mashup derived from Greek (alopecia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results